Business
DigiPath (DIGP) Earns Mention in "Bullish" Bank of America Merrill Lynch Research Report on Cannabis Investment Opportunities
DigiPath (DIGP) Earns Mention in "Bullish" Bank of America Merrill Lynch Research Report on Cannabis Investment Opportunities.
About this update from Hypha Labs, Inc.
[{"type":"text","content":"\n\n\n\nDigiPath (DIGP) Earns Mention in \"Bullish\" Bank of America Merrill Lynch Research Report on Cannabis Investment Opportunities\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nDigiPath (DIGP) Earns Mention in \"Bullish\" Bank of America Merrill Lynch Research Report on Cannabis Investment Opportunities\nPR Newswire\nLAS VEGAS, Dec. 17, 2015\n\n\n\nLAS VEGAS, Dec. 17, 2015 /PRNewswire/ -- DigiPath, Inc. (OTCQB: DIGP) was recently named in a Bank of America Merrill Lynch investment report on the opportunities emerging in the medical cannabis industry, entitled \"Medical Cannabis Has High POTential: A Joint Biotech & Tools Primer.\" The report is bullish on investments in the cannabis industry. It particularly singles out cannabis testing as an area likely to experience enormous growth.\n\n\n\"This analysis confirms what our own research has found, and what we've built our business model around: the legal cannabis sector is growing rapidly, and the demand for cannabis testing facilities will only increase as more states implement strict safety standards,\" notes Todd Denkin, president of DigiPath, Inc., and CEO of its cannabis testing unit, DigiPath Labs. \n\nAccording to the report, medical cannabis is already a $2.9 billion business and stands to at least double. The cannabis testing sector is estimated to reach $800–900 million by 2020. The report predicts increased demand for cannabis testing labs and the equipment they use to analyze cannabis. \n\nWhile the current US market \"consists primarily of small providers of testing and consulting services,\" the authors note that it is becoming increasingly regulated and standardized. \"While progress has been slow and much work remains to be done on the set up and implementation of a standard regulatory framework for the testing of cannabis products, there have been some recent steps in the right direction.\"\n\nAfter a thorough examination of the investment opportunities in cannabis testing, the analysts come to one clear conclusion: \"Bullish on the cannabis testing market and growth prospects for to...